期刊文献+

某院国家基本药物不良反应报告分析

Analysis of Adverse Reactions of National Essential Drugs in A Hospital
原文传递
导出
摘要 目的 了解现有国家基本药物发生药品不良反应(ADR)的情况和特点,促进基本药物安全、合理使用。方法 采用回顾性研究方法,依据2018版《国家基本药物目录》,抽取2019年1—12月蚌埠市第三人民医院上报的110份国家基本药物ADR报告进行统计分析。结果 ADR主要发生在年龄≥60岁人群(68例,61.8%);静脉滴注给药途径发生ADR患者73例(66.4%);引起ADR前两位的药品种类分别为抗肿瘤药(44例,40.0%)、抗微生物药(29例,26.4%);ADR主要累及消化系统(34例,29.6%)和皮肤附件(20例,17.4%),临床表现为恶心、皮疹、瘙痒、呕吐等。结论 加强国家基本药物ADR的预防和监测,保障患者用药安全。 Objective To understand the situation and characteristics of adverse drug reactions(ADRs)of existing national essential drugs,and promote the safe and rational use of essential drugs.Methods According to the 2018 edition of the National Essential Drugs Catalogue,110 national essential drug ADR reports reported by Bengbu Third People's Hospital from January 2019 to December 2019 were selected by retrospective study method,and the extracted reports were statistically analyzed.Results ADR mainly occurred in people aged≥60 years(68 cases,61.8%).ADR occurred in 73 cases(66.4%)by intravenous drip.The top two drugs causing ADR were anti-tumor drugs(44 cases,40.0%)and antimicrobial drugs(29 cases,26.4%).ADR mainly involved in digestive system(34 cases,29.6%)and skin appendages(20 cases,17.4%).The clinical manifestations were nausea,rash,itching and vomiting.Conclusion Strengthen the prevention and monitoring of ADR of national essential drugs to ensure the safety of basic drugs.
作者 王晨晨 WANG Chen-Chen(Department of Pharmaceutical,the Third People’s Hospital of Bengbu,Bengbu 233000,China)
出处 《中国药物经济学》 2023年第12期41-44,共4页 China Journal of Pharmaceutical Economics
关键词 药品不良反应 国家基本药物 分析 Adverse drug reactions National essential drugs Analysis
  • 相关文献

参考文献13

二级参考文献146

  • 1刘思源,郭代红,姚翀,杨鸿溢,孔祥豪,于承暄,朱雨,贾王平.18100例药源性过敏反应自发报告分析[J].药物流行病学杂志,2020,29(2):110-114. 被引量:8
  • 2赵艳艳,彭净,李兰芳,孟路华.133例喹诺酮类药品不良反应报告分析[J].中国合理用药探索,2019,16(2):101-104. 被引量:3
  • 3张丽梅,宋畅,蒋玉萍.复方丹参注射液与27种常用药物的配伍稳定性[J].中国药物与临床,2004,4(11):867-868. 被引量:6
  • 4王浴生,周黎明,洪诤.氟喹诺酮类药物不良反应的机制与化学结构的关系[J].药物不良反应杂志,2005,7(6):401-407. 被引量:64
  • 5陈新谦,金有豫,汤光.新编药物学[M].第17版.北京:人民卫生出版社,2011:32-33.
  • 6国家食品药品监督管理局药品安全监管司,国家药品不良反应中心编.药品不良反应报告和监测工作手册[S].2005:46.
  • 7Hatoum HT, Hutchinson RA, Lambert BL. Obrago: Patient Counseling-enhancing patient outcomes [ J ]. US Pharm, 1993,18(7) :76.
  • 8Rolfes L, van Hunsel F, Wilkes S, et al. Adverse drug re- action reports of patients and healthcare professionals-dif- ferences in reported information[J]. Pharmacoepidemiol Drug Saf, 2015,24(5) :2.
  • 9Ishigtu:o C, Hall M, Neyarapally GA, et al. Post-market drug safety evidence sources: an analysis of FDA drug safety communications[J]. Pharmacoepidemiol Drug Saf, 2012,21(10):1 134.
  • 10Kunnoor NS, Devi P, Kamath DY, et al. Age-and gen- der-related differences in drug utilisation and adverse drug reaction patterns among patients in a coronary care unit[J]. Singapore MedJ, 2014,55(4) :221.

共引文献181

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部